Journalartikel

Jahr der Veröffentlichung: 2017

Seiten: 3735-3740

Zeitschrift: Anticancer Research

Bandnummer: 37

Heftnummer: 7

ISSN: 0250-7005

eISSN: 1791-7530

Open Access Status: Bronze

DOI Link: https://doi.org/10.21873/anticanres.11747

Verlag: International Institute of Anticancer Research

Abstract: 
Aims: The aims of the present study were: (i) Evaluate specificity and sensitivity of Hb Smart enzyme-linked immunosorbent assay (ELISA) (ScheBo Biotech) compared to colonoscopy results and (ii) assess stability of a new sample collection device containing a newly formulated buffer to extract haemoglobin using buffer and stool samples spiked with defined concentrations of haemoglobin. Materials and Methods: Stool samples were quantified with the ELISA method. The stability of haemoglobin in the extraction buffer and in native stool samples, respectively, was determined daily by ELISA during storage for 5 days at 4 degrees C and at room temperature after addition of haemoglobin. Results: Haemoglobin ELISA had a sensitivity of 78.4% for detection of CRC with a specificity of 98%. Haemoglobin extracted in corresponding extraction buffer demonstrated stability throughout storage for 5 days at 4 degrees C and at room temperature. Conclusion: Hb Smart represents a very promising tool for large-scale screening of CRC with regard to sample handling, stability and analysis of haemoglobin in faeces.

Harvard-Zitierstil: Bruns-Toepler, M. and Hardt, P. (2017) Evaluation of a New Technique for iFOBT Utilising a New Sample Collection Device with Increased Buffer Stability, Anticancer Research, 37(7), pp. 3735-3740. https://doi.org/10.21873/anticanres.11747

APA-Zitierstil: Bruns-Toepler, M., & Hardt, P. (2017). Evaluation of a New Technique for iFOBT Utilising a New Sample Collection Device with Increased Buffer Stability. Anticancer Research. 37(7), 3735-3740. https://doi.org/10.21873/anticanres.11747